Activities
Broadening Molecular Testing in Non-Small Cell Lung Cancer: Optimizing Treatment With the Use of New and Emerging Biomarkers
0290-0000-21-068-H01-P
This activity will illustrate the current recommendations for biomarker testing in metastatic NSCLC.
2.00
Continuing the Conversation: Improving CAD/PAD Care Through Pharmacist Intervention
0290-0000-21-069-H01-P
This activity will focus on the pharmacist’s role in working with the health care team to improve quality of care and outcomes in patients with CAD and PAD. Clinical vignettes highlighting the patient encounter will be presented and assessed by the faculty.
0.50
Increasing Pharmacists' Awareness About Influenza Antivirals: Safety and Efficacy Data for Prevention and Treatment
0290-0000-21-066-L01-P
To ensure pharmacists are providing patients with the most up-to-date information, this session will enable them to be familiar with guidelines from leading organizations regarding use of antiviral therapy with the use of patient counseling video vignettes.
3-14-2021
1.50
Immune Checkpoint Inhibitor/Chemotherapy Combinations for Metastatic Triple-Negative Breast Cancer: Emerging Clinical Data and Managed Care Considerations
0290-0000-21-036-H01-P
This activity will determine the biological rationale for available and emerging treatment strategies involving immune checkpoint inhibitor (ICI)/chemotherapy combinations for the treatment of metastatic triple-negative breast cancer (mTNBC)
1.50